Robert L. Coleman, MD, FACOG, FACS | Authors

September 28, 2019

Robert L. Coleman, MD, FACOG, FACS, discusses the results of the phase III VELIA trial in patients with advanced ovarian cancer.

June 10, 2016

Robert L. Coleman, MD, discusses the importance of early BRCA testing for patients with ovarian cancer.

June 10, 2015

Robert L. Coleman, MD, FACOG, FACS, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the results of the ARIEL2 trial, a phase II study to identify patients with ovarian cancer likely to respond to rucaparib using tumor genetic analysis.

April 29, 2015

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses a study which examined the impact of bevacizumab in ovarian cancer.